Oncodesign Precision Medicine (FRA:ZR8) Cash per Share: €0.12 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ZR8 Oncodesign Precision Medicine SA FRA:ZR8
32 GF Score
Price €0.22
GF Value €0.25
! 1 Warning Sign
View Full Analysis

What is Oncodesign Precision Medicine Cash per Share?

Oncodesign Precision Medicine FRA:ZR8 +17.47% 32 Cash per Share is €0.12 as of Dec. 2025. GuruFocus rates FRA:ZR8 with a GF Score™ of 32/100 and a GF Value™ of €0.25. The stock has 1 warning sign investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Oncodesign Precision Medicine's Cash per Share for the quarter that ended in Dec. 2025 was €0.12.

Oncodesign Precision Medicine  (FRA:ZR8) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Oncodesign Precision Medicine Cash per Share Related Terms

Oncodesign Precision Medicine Cash per Share Historical Data

* Premium members only.

The historical data trend for Oncodesign Precision Medicine's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine Cash per Share Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial 4,921.31 0.81 0.63 0.29 0.12

Oncodesign Precision Medicine Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash per Share Get a 7-Day Free Trial 0.63 0.54 0.29 0.14 0.12
FRA:ZR8
32GF Score
Oncodesign Precision Medicine SA FRA:ZR8
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncodesign Precision Medicine Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Oncodesign Precision Medicine's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=2.11848084/18.45
=0.11

Oncodesign Precision Medicine's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=2.11848084/18.45
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of €0.12 mean?
Oncodesign Precision Medicine (FRA:ZR8) has a Cash per Share of €0.12 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for Oncodesign Precision Medicine and its competitors.
Is Oncodesign Precision Medicine's Cash per Share too high?
Oncodesign Precision Medicine's current Cash per Share is €0.12. Overall, Oncodesign Precision Medicine has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Cash per Share compare to VRTX and REGN?
Oncodesign Precision Medicine's Cash per Share of €0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Oncodesign Precision Medicine and its competitors. Oncodesign Precision Medicine's current Cash per Share is €0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Oncodesign Precision Medicine (FRA:ZR8) has a current Cash per Share of €0.12. The stock's GF Value™ is €0.25, compared to a current price of €0.22 — trading 12.8% below its estimated fair value. The current Cash per Share is €0.12. Oncodesign Precision Medicine's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Oncodesign Precision Medicine (FRA:ZR8), the current Cash per Share is €0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncodesign Precision Medicine (FRA:ZR8) Overvalued in 2026?

Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be undervalued. The current stock price of €0.22 is trading 12.8% below its estimated GF Value™ of €0.25.

Key valuation signals for FRA:ZR8:

  • Cash per Share: €0.12
  • GF Value™: €0.25 vs. price of €0.22 (12.8% below fair value)
  • GF Score™: 32/100 with 1 warning sign

No single metric tells the full story. See the FRA:ZR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncodesign Precision Medicine Business Description

Other Exchanges ALOPM:France
Address 18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
32GF Score

Get the complete analysis for FRA:ZR8

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.22
Price
€0.25
GF Value